U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H26N2O2.C4H6O4
Molecular Weight 480.5528
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLIFENACIN SUCCINATE

SMILES

OC(=O)CCC(O)=O.O=C(O[C@H]1CN2CCC1CC2)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5

InChI

InChIKey=RXZMMZZRUPYENV-VROPFNGYSA-N
InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)/t21-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C23H26N2O2
Molecular Weight 362.4647
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/vesicare-drug.htm https://www.drugs.com/mtm/solifenacin.html http://www.wikidoc.org/index.php/Solifenacin

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 nM [Ki]
125.0 nM [Ki]
25.0 nM [Ki]
7.73 null [pKi]
7.46 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VESICARE

Approved Use

VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1)

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
820 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
50.8 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
SOLIFENACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources: Page: p.1028
healthy, 19-40
n = 6
Health Status: healthy
Age Group: 19-40
Sex: M
Population Size: 6
Sources: Page: p.1028
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.1029
healthy, 20-35
n = 8
Health Status: healthy
Age Group: 20-35
Sex: M
Population Size: 8
Sources: Page: p.1029
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 1233
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 1233
Sources: Page: p.4
Disc. AE: Dry mouth...
AEs leading to
discontinuation/dose reduction:
Dry mouth (1.5%)
Sources: Page: p.4
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Disc. AE: Angioedema, Anaphylactic reaction...
AEs leading to
discontinuation/dose reduction:
Angioedema
Anaphylactic reaction (rare)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1.5%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 1233
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 1233
Sources: Page: p.4
Angioedema Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Anaphylactic reaction rare
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
2001 Jul
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
2002 Aug
Solifenacin demonstrates high absolute bioavailability in healthy men.
2004
Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
2004
Solifenacin: treatment of overactive bladder.
2004 Apr
Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children.
2004 Mar
Gateways to clinical trials.
2004 May
In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
2004 May 25
Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
2004 Oct
[Urinary incontinence: new pharmacologic therapies].
2004 Oct-Dec
[Neurological aspect of the hyperactive urinary bladder syndrome].
2005
[Medical therapy of urinary incontinence].
2005 Jan
Solifenacin and darifenacin for overactive bladder.
2005 Mar 14
The Q-T interval and antimuscarinic drugs.
2005 Nov
Solifenacin in the management of the overactive bladder syndrome.
2005 Oct
Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
2005 Sep
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
2005 Sep
Gateways to clinical trials.
2006 Apr
The causes and consequences of overactive bladder.
2006 Apr
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
2006 Aug
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
2006 Aug
New developments in the treatment of urinary incontinence.
2006 Dec
Solifenacin succinate (VESIcare): overactive bladder therapy.
2006 Dec
Newer agents for the management of overactive bladder.
2006 Dec 15
New drugs 06, part I.
2006 Feb
Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
2006 Jan
Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
2006 Jul
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
2006 Jul
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
2006 Jul
Gateways to clinical trials.
2006 Jul-Aug
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
2006 Mar
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
2006 Mar
Gateways to clinical trials.
2006 Nov
Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.
2007 Feb 28
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.
2007 Jan
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
2007 Jan
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
2007 Mar
An unusual cause of postoperative detrusor overactivity.
2007 Oct
Patents

Sample Use Guides

5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.
Route of Administration: Oral
The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:33:48 GMT 2023
Edited
by admin
on Fri Dec 15 16:33:48 GMT 2023
Record UNII
KKA5DLD701
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLIFENACIN SUCCINATE
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
YM67905
Code English
SOLIFENACIN SUCCINATE [USAN]
Common Name English
YM905
Code English
YM-67905
Code English
SOLIFENACIN SUCCINATE [USP-RS]
Common Name English
YM-905
Code English
SOLIFENACIN SUCCINATE [EP MONOGRAPH]
Common Name English
SOLIFENACIN SUCCINATE [VANDF]
Common Name English
VESICARE LS
Brand Name English
Solifenacin succinate [WHO-DD]
Common Name English
SOLIFENACIN SUCCINATE [ORANGE BOOK]
Common Name English
SOLIFENACIN SUCCINATE [MI]
Common Name English
SOLIFENACIN SUCCINATE [JAN]
Common Name English
SOLIFENACIN SUCCINATE [MART.]
Common Name English
VESICARE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
Code System Code Type Description
SMS_ID
100000090370
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
RXCUI
477365
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
ALTERNATIVE
NCI_THESAURUS
C73805
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
DAILYMED
KKA5DLD701
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
MERCK INDEX
m10108
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY Merck Index
PUBCHEM
216457
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
EVMPD
SUB21028
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
MESH
C441209
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
RXCUI
476588
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
DRUG BANK
DBSALT001639
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
USAN
MM-33
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID30947075
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
FDA UNII
KKA5DLD701
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
RS_ITEM_NUM
1615300
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
CAS
242478-38-2
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL1734
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY